en · de · es · fr · pt
tesamorelin-notes.peptides5388.com › Info › Background And Clinical Development — Practical Notes

Background And Clinical Development — Practical Notes

By Editorial Desk · published 2025-07-30 · last reviewed 2025-09-01 · Info

Everything below concerns 内脏脂肪. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-09-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Clinical Development

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Background and Clinical Profile

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Tesamorelin at a glance

PropertyValueNotes
Molecular weightApproximately 5,136 DaBased on the 44-amino-acid peptide backbone and N-terminal modification.
AppearanceWhite to off-white lyophilized powderUsually supplied in single-use vials for reconstitution.
SolubilityFreely soluble in water; slightly soluble in some organic solventsPeptide nature supports aqueous reconstitution.
Typical storage2–8 °C, protected from lightRefrigeration reduces degradation; avoid freezing unless specified.
Common analytical methodReverse-phase high-performance liquid chromatographyUsed for identity, purity, and quantification.
SynonymsTesamorelin, TH9507, GHRH(1-44) analogGeneric descriptors; avoid proprietary names.

tesamorelin 背景与作用机制

tesamorelin 是一种人工合成的四十四肽,序列与内源性生长激素释放激素(GHRH)的 1-44 片段一致,区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割,从而延长分子在循环中的存留时间。作为肽类分子,它难以经胃肠道吸收,文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物,以区别于生长激素本身。

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶,升高细胞内 cAMP,再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点,生长激素仍以脉冲方式分泌,而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生,构成完整的生长激素轴响应。

Related pages on this site

Supporting material

== Radioactive dating == 238U abundance and its decay to daughter isotopes comprises multiple uranium dating techniques and is one of the most common radioactive isotopes used in radiometric dating. The most common dating method is uranium-lead dating, which is used to date rocks older than 1 million years old and has provided ages for the oldest rocks on Earth at 4.4 billion years old. The relation between 238U and 234U gives an indication of the age of sediments and seawater that are between 100,000 years and 1,200,000 years in age. The 238U daughter product, 206Pb, is an integral part of lead–lead dating, which is most famous for the determination of the age of the Earth. The Voyager program spacecraft carry small amounts of initially pure 238U on the covers of their golden records to facilitate dating in the same manner.

Dylan Thomas was born on 27 October 1914 in Swansea, the son of Florence Hannah (née Williams; 1882–1958), a seamstress, and David John 'Jack' Thomas (1876–1952), a teacher. His father had a first-class honours degree in English from University College, Aberystwyth, and ambitions to rise above his position teaching English literature at the local grammar school. Thomas had one sibling, Nancy Marles (1906–1953), who was eight years his senior. The red-brick, semi-detached house at 5 Cwmdonkin Drive (in the Uplands area), in which Thomas was born and lived until he was 23, had been bought by his parents a few months before his birth. At the 1921 census, Nancy and Dylan are noted as speaking both Welsh and English. Their parents were also bilingual in English and Welsh, and Jack Thomas taught Welsh at evening classes. One of their Swansea relations has recalled that, at home, "Both Auntie Florrie and Uncle Jack always spoke Welsh." There are three accounts from the 1940s of Dylan singing Welsh hymns and songs, and of speaking a little Welsh. Thomas's father chose the name Dylan, which could be translated as "son of the sea" after Dylan ail Don, a character in The Mabinogion. His middle name, Marlais, was given in honour of his great-uncle, William Thomas, a Unitarian minister and poet whose bardic name was Gwilym Marles. The name Dylan being pronounced [ˈdəlan] in Welsh caused his mother to worry that he might be teased as the "dull one". When he broadcast on Welsh BBC early in his career, he was introduced using this pronunciation.

==== Marquez: The Wannabe B-Boy ==== Meet Marquez, a street fighter who makes life miserable for twins Richard and Edward. Mayhem brings in Brazilian jiu-jitsu specialist, Quinn Mulhern standing at 6'3 and weighing in at 177 lbs, with a record of 14 wins and 1 loss to put him in his place. This episode has never aired on American TV and is not available on the Bully Beatdown website like most other episodes. The episode has been aired in the Netherlands, the Fox8 channel of Foxtel and Austar in Australia, and MTV Latin America. Many have speculated that the bully winning more money is the reason why it was never broadcast in America.

Sources: en.wikipedia.org

Supporting material

=== Restructuring and acquisition by Embracer Group (2015–2024) === Gearbox established Gearbox Publishing in 2015, first announced to the public in December 2016, as to publish third-party games, starting with the remastered version of Bulletstorm from People Can Fly. Pitchford said that it wanted to start expanding into other areas of capital growth beyond games that Gearbox was traditionally known for, and planned to use Gearbox Publishing as a starting point. Later, in May 2019, Gearbox established The Gearbox Entertainment Company, Inc. (Gearbox Entertainment) as a parent company for both Gearbox Software and Gearbox Publishing. Co-founder Landon Montgomery, who had left the company around 2007, died on March 25, 2020. In April 2021, Gearbox Entertainment was wholly acquired by the Embracer Group for precisely $363 million rising to $1.378 billion should it reach specific operational targets. This addition would be the company's seventh major publishing group. Pitchford stated that while it was looking to raise capital from 2016, it came to meet with Embracer, and saw that its decentralized studio model would work well for Gearbox. 2K remained on Gearbox's board and continued to publish the Borderlands series. Gearbox Entertainment opened a second Canadian studio, Gearbox Studio Montreal, in August 2021, to support 250 new staff, bringing the total size of Gearbox to around 850 employees.

=== United States === In January 2009, the Alfred P. Sloan Foundation funded the Woodrow Wilson Center, the Hastings Center, and the J. Craig Venter Institute to examine the public perception, ethics and policy implications of synthetic biology. On July 9–10, 2009, the National Academies' Committee of Science, Technology & Law convened a symposium on "Opportunities and Challenges in the Emerging Field of Synthetic Biology". After the publication of the first synthetic genome and the accompanying media coverage about "life" being created, President Barack Obama established the Presidential Commission for the Study of Bioethical Issues to study synthetic biology. The commission convened a series of meetings, and issued a report in December 2010 titled "New Directions: The Ethics of Synthetic Biology and Emerging Technologies." The commission stated that "while Venter's achievement marked a significant technical advance in demonstrating that a relatively large genome could be accurately synthesized and substituted for another, it did not amount to the "creation of life". It noted that synthetic biology is an emerging field, which creates potential risks and rewards. The commission did not recommend policy or oversight changes and called for continued funding of the research and new funding for monitoring, study of emerging ethical issues and public education. Synthetic biology, as a major tool for biological advances, results in the "potential for developing biological weapons, possible unforeseen negative impacts on human health ... and any potential environmental impact".

Orlando Figes (born 1959) historian, author, known for works on Russian history; has also contributed on European history with his book The Europeans (2019); has served on editorial board of journal Russian History; writes for international press, broadcasts on television and radio, reviews for The New York Review of Books, and is fellow of Royal Society of Literature; was historical consultant on film Anna Karenina starring Keira Knightley and Jude Law with screenplay by Tom Stoppard; historical consultant on BBC War & Peace television series. Antonia Forest (26 May 1915 – 28 November 2003) was the pseudonym of Patricia Giulia Caulfield Kate Rubinstein, an English writer. She wrote 13 books for children, published between 1948 and 1982. Her 10 best-known works concern the doings of the fictional Marlow family. Forest also wrote two historical novels about the Marlows' Elizabethan ancestors. Dov Forman (b. 2003); author and social media creator; uses social media to educate people about the Holocaust and Judaism, and to advocate against antisemitism; co-authored Lily's Promise, a book documenting the Holocaust; received the 'Points of Light' award for services to Holocaust education; included in the inaugural TIME100 Creators list; was selected for the inaugural Masa Changemakers List, honouring 18 global leaders from Masa's 200,000+ alumni. Forman was a Masa participant during his time in Israel as a Nitzavim Fellow, studying at the Hebrew University of Jerusalem and a Talmudic college in Jerusalem.

Sources: en.wikipedia.org

Frequently asked questions

What is tesamorelin?

It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.

Which patient group was studied in pivotal trials?

Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.

What remains uncertain about its long-term effects?

Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.

What is tesamorelin?

It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.

Network